JAN 12, 2016 9:00 PM PST

Gene that stops tumors may spread colorectal cancer

A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer.

The discovery may lay the foundation for new colorectal cancer treatments.
 
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States.

“The gene known as Sprouty2 has previously been shown to protect against metastasis, or the spreading of cancer to other parts of the body, in breast, prostate, and liver cancer,” says Sharad Khare, associate professor of research in the University of Missouri School of Medicine’s Division of Gastroenterology and Hepatology and lead author of the study that is published in the journal Oncogene.

“However, our recent molecular studies found that this gene may actually help promote metastasis instead of suppress it.”

For more than three years, researchers have studied Sprouty2 in cancer cell models, mouse models, and human biopsy samples. Using different molecular methods, the researchers found that the gene functions differently in colorectal cancer than in other types of cancers.

Sprouty2 is known to block molecular circuits to prevent cancer cells from growing and spreading to other parts of the body. However, in colorectal cancer, Sprouty2 may increase the metastatic ability of cancer cells instead of suppress it. Khare believes this occurs when the gene is up-regulated, or supercharged.

Cancer deaths attributed to colorectal cancer are mainly due to tumor recurrence and metastasis to other organs. Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, according to the American Cancer Society. It’s estimated that the lifetime risk of developing colorectal cancer is about 1 in 20.

“This finding is a very significant step in our understanding of metastasis in colorectal cancer, but it’s important to note that we believe this phenomenon may occur in only a subset of colorectal cancer patients,” Khare says.

“We don’t yet know why this is the case, but we hope to determine if there is a correlation between the up-regulation of this gene and the life expectancy of patients with colorectal cancer. Future studies will help us understand who may be at risk, and ultimately, if personalized treatments can be planned to target this gene.”

The National Institutes of Health, a Veterans Affairs Merit Award, the MU Research Board Award and MU School of Medicine Bridge funded the work. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

This article was originally published on futurity.org
About the Author
  • Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
SEP 10, 2020
Cancer
Pancreatic cancer patients see hope in this newly developed drug
SEP 10, 2020
Pancreatic cancer patients see hope in this newly developed drug
A new drug developed by researchers at the University of Sheffield hopes to improve life expectancy and quality of life ...
SEP 30, 2020
Cancer
Chemokines Could be the Key in Controlling Glioma Stem Cells
SEP 30, 2020
Chemokines Could be the Key in Controlling Glioma Stem Cells
The transformation of a healthy cell into a cancerous one often comes with a slew of cellular signaling changes.  T ...
NOV 18, 2020
Genetics & Genomics
Choosing an NGS workflow: What are you looking for?
NOV 18, 2020
Choosing an NGS workflow: What are you looking for?
  It’s easy to be overwhelmed by the number of workflows that are available for NGS. How do you choose? While ...
NOV 09, 2020
Cancer
A Prognostic Expression Profile for Osteosarcoma
NOV 09, 2020
A Prognostic Expression Profile for Osteosarcoma
Tireless research goes into every cancer diagnostic tools and new therapy. Many types of cancer have made giant steps fo ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 14, 2020
Cancer
New intravenous anti-cancer therapy crosses blood-brain barrier
NOV 14, 2020
New intravenous anti-cancer therapy crosses blood-brain barrier
New research from the University of Michigan reports for the first time a new synthetic protein nanoparticle that is abl ...
Loading Comments...